放弃生命支持治疗后从ICU出院的癌症患者结局
这项回顾性研究在肿瘤医院ICU开展,纳入16998例成人癌症患者,其中1369例(8.1%)在ICU期间做出放弃生命支持治疗决定,507例随后从ICU出院并纳入分析。该组院内死亡率为80.1%,ICU期间发生谵妄或急性肾损伤独立预测院内死亡;6个月和12个月生存率分别为3.6%和0.6%。64例(12.6%)恢复癌症治疗、52例(10.3%)再入ICU,二者生存均更长(p<0.01)。放弃生命支持治疗决定与更高院内死亡率相关(80.0% vs 26.3%,p<0.01)。
要点
- 放弃生命支持治疗后从ICU出院的癌症患者,院内死亡率80.1%,6个月生存率3.6%,12个月生存率0.6%。
- ICU期间发生谵妄或急性肾损伤是该组院内死亡的独立预测因素。
- 放弃生命支持治疗决定与更高院内死亡率相关(80.0% vs 26.3%,p<0.01),倾向性评分法显示独立关联。
- 出院后恢复癌症治疗者64例(12.6%)、再入ICU者52例(10.3%),二者生存均更长(p<0.01)。
- 作者认为了解这些结局有助于为患者及家属提供恰当的治疗规划和咨询。
适用人群与场景
- 肿瘤医院ICU收治的成人癌症患者,且在ICU期间做出放弃生命支持治疗决定后从ICU出院者(507例)。
- 源人群为16998例入住ICU的成人癌症患者,其中1369例(8.1%)在ICU期间做出放弃生命支持治疗决定。
研究设计与关键结果
- 回顾性研究,肿瘤医院ICU,16998例入住ICU的成人癌症患者中1369例(8.1%)在ICU期间做出放弃生命支持治疗决定,其中507例从ICU出院并纳入分析。
- 该507例患者院内死亡率为80.1%,ICU期间发生谵妄或急性肾损伤独立预测院内死亡。
- 6个月和12个月生存率分别为3.6%和0.6%。
- 64例(12.6%)恢复癌症治疗、52例(10.3%)再入ICU,二者生存均更长(p<0.01)。
- 倾向性评分法显示放弃生命支持治疗决定与更高院内死亡率相关(80.0% vs 26.3%,p<0.01),并与更低生存率相关(p<0.01)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,了解放弃生命支持治疗后从ICU出院的癌症患者的这些结局,对为患者及家属提供恰当的治疗规划和咨询很重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Many cancer patients are admitted to an ICU and decisions to forgo life-sustaining therapies are frequent during ICU stay. A significant proportion of these patients are subsequently discharged from ICU, but their outcomes are unknown.
DESIGN: Retrospective.
SETTING: ICU of oncological hospital.
PATIENTS: Adult cancer patients admitted to ICU, then with a decision to forgo life-sustaining therapies and that were discharged from ICU.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Hospital mortality, long-term survival, recommencement of cancer treatment, and ICU readmission were recorded. Hospital mortality predictors were evaluated. The propensity score method was used to test the hypothesis that decision to forgo life-sustaining therapies was independently associated with hospital mortality. Among the 16,998 patients that were admitted to ICU, in 1,369 patients (8.1%) a decision to forgo life-sustaining therapies was made during ICU stay. Among the latter group, 507 were discharged from ICU and were examined in this study. The hospital mortality of this group was 80.1% and was independently predicted according to the occurrence of delirium or acute kidney injury during their ICU stay. Six-month and 12-month survival rates were 3.6% and 0.6%. Sixty-four patients (12.6%) resumed cancer treatment and had a longer survival (p < 0.01). Fifty-two patients (10.3%) were readmitted to ICU and had a longer survival (p < 0.01). The decision to forgo life-sustaining therapies was associated with higher hospital mortality (80.0% vs 26.3%, respectively; p < 0.01) and lower rates of survival (p < 0.01).
CONCLUSIONS: Approximately 20% of cancer patients discharged from our ICU after a decision to forgo life-sustaining therapies were discharged from hospital. Delirium and acute kidney injury during ICU stay were predictors of hospital mortality. The decision to forgo life-sustaining therapies was independently associated with hospital mortality. Patients readmitted to the ICU and those that resumed cancer treatment had longer survival. Knowledge of these outcomes is important for providing proper therapeutic planning and counseling for patients and their relatives.
参考来源
- Praça APA, Nassar AP, Caruso P, et al. Outcomes of Cancer Patients Discharged From ICU After a Decision to Forgo Life-Sustaining Therapies. Crit Care Med. 2019. PMID: 30889028. doi:10.1097/CCM.0000000000003729
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。